Publication Name	World Journal of Virology
Manuscript ID	70779
Country	Germany

Received	2021-08-14 08:26
Peer-Review Started	2021-08-14 08:31
First Decision by Editorial Office Director	2021-09-02 06:37
Return for Revision	2021-09-02 06:37
Revised	2021-09-08 06:51
Publication Fee Transferred
Second Decision by Editor	2022-02-08 05:59
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2022-02-10 16:21
Articles in Press	2022-02-10 16:21
Edit the Manuscript by Language Editor	2022-01-28 22:41
Typeset the Manuscript	2022-03-21 01:51
Publish the Manuscript Online	2022-03-22 04:46

ISSN	2220-3249 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Virology
Manuscript Type	Letter to the Editor
Article Title	Bacterial and fungal co-infection is a major barrier in COVID-19 patients: A specific management and therapeutic strategy is required
Manuscript Source	Invited Manuscript
All Author List	Tarun Sahu, Henu Kumar Verma and Lakkakula V K S Bhaskar
Funding Agency and Grant Number
Corresponding Author	Henu Kumar Verma, PhD, Research Scientist, Senior Researcher, Department of Immunopathology, Institute of Lung Health and Immunity, Comprehensive Pneumology Center, Helmholtz Zentrum, Neuherberg Inglostäder Landstrapβe 1, Munich 85764, Germany. henu.verma@yahoo.com
Key Words	COVID-19; Co-infection; Bacterial co-infection; Fungal co-infection
Core Tip	The immune systems of coronavirus disease 2019 patients are already compromised, making them vulnerable to bacterial, fungal, and viral co-infections. These secondary infections, also known as co-infections, are hospital-acquired/nosocomial infections, and mechanically ventilated patients are especially vulnerable. There are no specific guidelines or treatment options for these types of co-infections at the moment, which is contributing to an increase in morbidity and mortality among these patients.
Publish Date	2022-03-22 04:46
Citation	Sahu T, Verma HK, Bhaskar LVKS. Bacterial and fungal co-infection is a major barrier in COVID-19 patients: A specific management and therapeutic strategy is required. World J Virol 2022; 11(2): 107-110
URL	https://www.wjgnet.com/2220-3249/full/v11/i2/107.htm
DOI	https://dx.doi.org/10.5501/wjv.v11.i2.107

Full Article (PDF)	WJV-11-107.pdf
Full Article (Word)	WJV-11-107.docx
Manuscript File	70779_Auto_Edited-JRF-Filipodia CL.docx
Answering Reviewers	70779-Answering reviewers.pdf
Audio Core Tip	70779-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	70779-Conflict-of-interest statement.pdf
Copyright License Agreement	70779-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	70779-Language certificate.pdf
Peer-review Report	70779-Peer-review(s).pdf
Scientific Misconduct Check	70779-Bing-Fan JR-2.png
Scientific Editor Work List	70779-Scientific editor work list.pdf
CrossCheck Report	70779-CrossCheck report.pdf
CrossCheck Report	70779-CrossCheck.png